What is Urovant Sciences?
Founded in 2016 and headquartered in London, United Kingdom, Urovant Sciences is dedicated to the development and commercialization of novel therapies targeting urologic conditions. The company's focus on unmet needs within the urology space positions it as a key player in advancing patient care through innovative pharmaceutical solutions.
How much funding has Urovant Sciences raised?
Urovant Sciences has raised a total of $300M across 1 funding round:
Debt
$300M
Debt (2019): $300M with participation from Sumitomo Dainippon Pharma Co.
Key Investors in Urovant Sciences
Sumitomo Dainippon Pharma Co.
Sumitomo Dainippon Pharma Co. is a global pharmaceutical company with a broad portfolio, likely contributing strategic expertise and capital to advance Urovant Sciences' therapeutic development.
What's next for Urovant Sciences?
The substantial enterprise-level funding, including the recent strategic investment, provides Urovant Sciences with the necessary resources to accelerate its development pipeline and commercialization efforts. This capital infusion is expected to fuel further research, clinical trials, and market penetration, solidifying the company's growth and its commitment to addressing critical urologic health challenges.
See full Urovant Sciences company page
